Home > Keywords > Mise en page > page_accueil_3_actus

page_accueil_3_actus

Articles

  • Meet Vect-Horus at the 3rd Annual Next Gen Lipid-Based Nanoparticles Delivery Summit, Boston, August 21-23, 2024
    21 August 2024, by Emmanuelle BETTENDORF

    VECT-HORUS S.A.S. will be presenting a poster at the 3rd Annual Next Gen Lipid-Based Nanoparticles Delivery Summit!
    This high-profile event is taking place in Boston, MA from August 20-22, and Pavlo Shpak-Kraievskyi, Project leader, is looking forward to attending.
    Poster Title: VECTrans® Technology for CNS Targeting by Lipid Nanoparticles
    📆 Save the date: 3:30pm ET, Wednesday August 21st
    🌐 Learn More: https://ter.li/b5vw3f

  • RadioMedix and Vect-Horus Announce First Patient Dosed in Exploratory Clinical Study of 203Pb-RMX-VH-PIB for GBM and PDAC
    19 September, by Emmanuelle BETTENDORF

    Together with our partner Radiomedix, Inc. , we have successfully dosed the first patient in an exploratory Investigational New Drug study evaluating the diagnostic 203Pb-RMX-VH-PIB in Glioblastoma Multiforme (GBM) and Pancreatic ductal adenocarcinoma (PDAC).
    “The initiation of this clinical trial is an important milestone for Vect-Horus and demonstrates continuing progress in the collaboration with our partner RadioMedix,” says Alexandre Tokay, CEO of Vect-Horus.
    “We are looking forward (…)

  • Secarna Pharmaceuticals and Vect-Horus Announce Research Collaboration to Advance Systemic Delivery of RNA-Targeted Therapeutics for CNS Disorders
    11 July, by Emmanuelle BETTENDORF

    We are proud and excited to announce a new strategic research collaboration with Secarna Pharmaceuticals!
    The partnership will focus on developing RNA-targeted therapeutics capable of crossing the blood-brain barrier (BBB) to address diseases of the central nervous system (CNS), combining our delivery technology platform, VECTrans®, with Secarna’s proprietary OligoCreator® oligonucleotide discovery platform.
    The combination of these two technologies will expand Secarna’s targeted (…)

  • Meet Vect-Horus at BIO Japan, October 8-10, 202
    19 September, by Emmanuelle BETTENDORF

    We are excited to be attending BioJapan, taking place October 8-10.
    Our Senior Business Developer Faustine Ramel will be in Yokohama for the event – please let us know if you would like to schedule a meeting.
    https://jcd-expo.jp/en/

  • Our latest research article is now available on bioRxiv and medRxiv
    11 July, by Emmanuelle BETTENDORF

    In this study, we explored the identification and optimization of cross-species reactive VHHs (single-domain antibodies from camelids) targeting the transferrin receptor 1 (TfR1) — a promising strategy for delivering therapeutics across the blood-brain barrier.
    We focused on two candidates, C5 and B8, which bind TfR1 in rodents, non-human primates, and humans. These VHHs show potential as molecular shuttles for transporting imaging or therapeutic agents across species — paving the way for (…)

  • How blood–brain barrier technology is unleashing CNS therapies
    19 September, by Emmanuelle BETTENDORF

    Nature Research has republished an in-depth article on Vect-Horus in the September issue of Biopharma Dealmakers. The issue focuses on CNS related technologies and therapeutics.
    It’s well worth having a read, or re-read, of this piece, which outlines our VECTrans platform and its potential to transform the treatment of neurodegenerative disorders.
    It also touches on the science and data behind our approach and our partnerships with Novo Nordisk Radiomedix, Inc. and Ionis Pharmaceuticals, (…)

  • Vect-Horus appoints Carole Imbert as Chief Financial Officer to further reinforce its executive management team
    25 March, by Emmanuelle BETTENDORF

    We are thrilled to welcome Carole Imbert to our executive management team as our new Chief Financial Officer.
    “Her extensive background in financial strategy and investor relations will be complementary to our existing skilled team, and an invaluable asset to drive our growth and secure a strong financial position to underpin development of our vectors that facilitate targeting and delivery of therapeutics,” says @Alexandre Tokay, co-founder and CEO of Vect-Horus.
    “Carole’s leadership (…)

  • Vect-Horus announces agreement with Johnson&Johnson Innovation
    18 January 2019, by Jonathan NOWAK

    Vect-Horus announced today the signing of a research collaboration agreement with Janssen Pharmaceuticals, Inc. one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

  • Meet Vect-Horus at OTS, Montreal, October 6-9, 2024
    2 October 2024, by Emmanuelle BETTENDORF

    Guillaume Jacquot and Emmanuelle Bettendorf will be representing Vect-Horus at the The Oligonucleotide Therapeutics Society (OTS) Annual Meeting, taking place in Montreal, Canada from October 6-9.
    This is the leading international meeting of renowned oligonucleotide scientists, bringing academia, research and business together, and we are excited to swap notes with other leading players in the field.
    👉 Click here for more on the meeting www.2024oligomeeting.com

  • TIDES Europe: Oligonucleotide & Peptide Therapeutics in AMSTERDAM
    31 October 2019, by Elodie DORMES

    Dr Guillaume JACQUOT will present "Targeted Drug Delivery to the CNS and Peripheral Tissues Using the VECTrans® Innovative Technology" during the TIDES Europe, 12-15 November 2019.